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Approximately 10% of children born small for their gestational age (SGA) fail to show catch-up growth and may
remain short-statured as adults. Despite treatment guidelines for children born SGA that recommend referral for
growth hormone (GH) therapy evaluation and initiation by ages 2 to 4 years, the average age of GH treatment
initiation is typically much later, at ages 7 to 9 years. Delayed referral for GH treatment is problematic as studies
show younger age at GH treatment initiation in children born SGA is an independent predictor for responses such
as optimal growth acceleration, normalization of prepubertal height, and most importantly, adult height (AH). This
review discusses the importance and associated challenges of early diagnosis of children born SGA who fail to
show catch-up growth, contrasts the recommended age of referral for these patients and the average age of GH
treatment initiation, and discusses studies showing the significant positive effects of early referral and treatment
with GH on AHs in short-statured children born SGA. To optimize the eventual height in short-statured SGA
children who fail to manifest catch-up growth, a lowering of the average age of referral for GH therapy evaluation
is needed to better align with consensus recommendations for SGA management. The importance of increasing
parental and physician awareness that most children born SGA will do well developmentally and will optimally
benefit from early initiation of GH treatment when short-statured is addressed, as is the need to shift the age of
referral to better align with consensus recommendations.
Keywords: Hormone, GH therapy, Referral age, Short-statured, Optimal height acceleration, Gestational age,
Prepubertal height, Adult heightIntroduction
Being small for gestational age (SGA) at birth has many
causes, including fetal, placental, maternal, and environ-
mental factors [1,2]. SGA is typically diagnosed when
birth weight and/or length are at least 2 standard devia-
tions (SDs) below the mean for gestational age, using
appropriate reference data [1,3]. Children born SGA
comprise a heterogeneous group with a broad spectrum
of clinical characteristics [4]. SGA may occur alongside
intrauterine growth retardation (IUGR) and/or premature
birth, or may be diagnosed at term in the absence of any
prenatal complications. The etiology of SGA is frequently* Correspondence: plee@psu.edu
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reproduction in any medium, provided the orunknown, and current estimates suggest that 40% of SGA
births will have no identifiable pathology. Of those 60% of
SGA infants where an etiology is identified, about 50%
involve maternal factors, 5% involve fetal abnormalities,
and less than 5% are felt to be due to placental pathology.
Maternal factors associated with SGA include inadequate
nutrition; hypoxia; diabetes mellitus; drug use and abuse;
vascular, hematologic, and renal disorders; infection; and
sociodemographic factors. Fetal causes include congenital
anomalies; chromosomal abnormalities; infection; and
hormone abnormalities involving insulin, leptin, thyroid
hormones, and insulin-like growth factors (IGF-1 and
IGF-2). Placental factors that may result in SGA include
placental insufficiency, infarction, abruption, and vascular
abnormalities [1,5-8].
The available SGA incidence and prevalence data are
limited due to insufficient or inconsistent records forl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[9]. A population-based study including 3650 healthy
full-term neonates born in Sweden over a 3-year period
found 5.4% (N= 198) were diagnosed SGA, defined as<−2
SDs in birth length and/or weight [10]. Within the group
of SGA children, 1.5% were both underweight and short,
2.4% were short only, 1.6% were underweight only. The
estimated incidence of SGA births, using the definition of
<−2 SDs in length or weight (equivalent to the 2.3 percent-
ile), is 1 in 43, making SGA incidence relatively high com-
pared with other growth disorders [11]. Most children born
SGA show catch-up growth, generally defined as growth
velocity (cm/year) greater than the median for chronologic
age and gender, within the first 2 years of life; however, ap-
proximately 10% fail to show catch-up growth and may re-
main short-statured as adults [1]. Growth hormone (GH)
therapy has been approved for long-term therapy of growth
failure in short-statured children born SGA who show no
evidence of catch-up growth by age 2 to 4 years [1,3,12].
The mechanisms underlying catch-up growth remain un-
clear [13]. Lack of catch-up growth has not been associated
with any specific SGA etiology; however, preterm birth with
less than 32 weeks gestation has been associated with a
greater risk for no catch-up growth [3,14].
The average age of GH treatment initiation in short-
statured children born SGA is typically many years later
than the recommended age of 2 to 4 years [3,15-17].
This frequent delay in GH treatment is problematic as
older age at GH therapy initiation is associated with
significantly reduced growth response [15,18-20]. This
review discusses the importance and associated challenges
of early diagnosis of SGA with failure of spontaneous
catch-up growth. We contrast the recommended age of
referral and GH treatment initiation, according to con-
sensus-based guidelines, with the average age(s) reported
in treatment studies; we then review the significant posi-
tive benefits of early GH treatment on optimal height out-
comes in short-statured patients born SGA.
Diagnosis of SGA
Accurate gestational age dating and measurement of
birth weight and length are critical for SGA diagnosis
[3]. There are several challenges to achieving accurate
gestational age dating and accurate birth weight and
length measurement. The accuracy of gestational age
dating depends on the method used. An estimate based
on last menstrual period produces greater error com-
pared with clinical or obstetric estimates using early
ultrasound assessment [21-24]. Accurate assessment of
growth restriction requires careful and precise neonatal
measurements, which are essential to establish size rela-
tive to gestational age [25-27]. Additionally, appropriate
use of population-relevant reference growth curves is
also necessary for accurate diagnosis of SGA [28,29].Discriminating between pathologic and constitutional
SGA is difficult, and guidelines for the selection of
appropriate reference comparison data are evolving. The
anthropometric definition of SGA does not account for
background growth-modifying factors, such as maternal
height, weight, ethnicity, and parity [3,30]. These modify-
ing factors can be used to statistically model a corrected
birth weight and/or length, and may increase the likeli-
hood of identifying abnormal fetal growth compared with
constitutional smallness [30]. This approach to growth
assessment adjusts for physiological variation, calculates
true growth potential, and creates individually customized
fetal, neonatal, and child growth curves and birth weight
percentiles [30-33]. Methodology for customized growth
assessment is currently being developed and is not yet
widely available.
To expedite appropriate early referral to GH treat-
ment, early diagnosis of SGA and recognition of failure
of spontaneous catch-up growth are critical [1,3]. Mea-
surements of length, weight, and head circumference
should be taken every 3 months in the first year of life
and every 6 months thereafter [3]. Diminished head
growth, particularly when it occurs both in utero and
postnatally, is especially important to follow. Little or no
catch-up head growth is a significant risk factor for poor
outcome as it has been associated with widespread cog-
nitive impairments [34]. Spontaneous catch-up growth
typically occurs by age 2, and is most pronounced in the
first 6 to 12 months after birth [1,3]. A child without
spontaneous catch-up growth by age 3, or by age 4 in
preterm infants, is unlikely to experience it later without
therapeutic intervention [1,3]. It has been shown that
children born SGA have a 7-fold higher risk of being
short at age 18 than do children not born SGA, and
children born SGA comprise 22% of adults whose
height is below −2 SD scores (SDs) [35].
Indication for GH treatment
GH treatment of short children born SGA has been
approved by the US Food and Drug Administration (FDA)
since 2001 and the European Medicines Agency (EMA)
since 2003 [1,3,11]. Prior to initiating GH treatment, other
causes of short stature must be excluded, including
growth-inhibiting medication, chronic diseases, endocrine
disorders, emotional deprivation, or syndromes associated
with short stature. GH stimulation testing or the presence
of GH deficiency (GHD) are not required prior to GH
treatment of children born SGA as the growth benefit
from GH treatment occurs whether GHD is present or
not [36-38]. No correlation has been found between
spontaneous 24-hour GH profiles or maximal stimulated
GH secretion before the start of GH treatment and adult
height (AH) SDS or gain in height SDS in children born
SGA [37].
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portunity for spontaneous catch-up growth has passed
[1,3,35,39]. In the US, treatment is indicated in children
born SGA who fail to achieve normal growth velocity by
age 2. The EMA indication approves GH treatment begin-
ning at age 4 [3]. The International Societies of Pediatric
Endocrinology and the Growth Hormone Research Soci-
ety consensus statement proposes that children born SGA
with height below −2.5 SDs at age 2, or with height below
−2 SDs at age 4, should be GH treatment eligible [3].
Thus, by age 4, initiation of GH treatment is broadly
recommended in SGA children with short stature when
the family feels AH is important.
Early referral for GH treatment
The average age of GH treatment initiation in children
born SGA is frequently much older than the 2- to 4-year-
old age range recommended by consensus guidelines
[3,15,40]. Among 360 GH-naïve, born-SGA pediatric
patients participating in the American Norditropin Stud-
ies: Web-Enabled Research (The ANSWER ProgramW)
registry, the mean age at treatment initiation was
8.4 years [15], and among 1909 children born SGA
enrolled in the Pfizer International Growth Database
(KIGS; a pharmacoepidemiological survey of children
treated with GH) the mean age at start of GH therapy
was 9.1 years (range, 3.9-13.3) [17]. Significant variation
in age of referral and GH treatment initiation for short-
statured SGA patients has been shown among different
countries, ranging from a mean age of 6.7 to a mean age
of 9.3 [16]. The older-age treatment referral and initiation
is problematic as SGA patients beginning GH therapy at
ages 9–10 experience lower growth velocity and have
shorter AHs compared with those treated earlier [1].
The reasons for the current practice of delayed referral
are unclear. One possibility is that parent attitudes and
preferences regarding treatment influence physician
decision making. For example, physicians were 40%
more likely to recommend GH therapy for a child with
short stature, not specific to SGA, if the family strongly
desired GH treatment compared with a family neutral
about treatment [41]. Parental realization of the import-
ance of optimal growth may be delayed due to the pres-
ence of other comorbid conditions during the early
developmental period of their child born SGA. Parents
of children born with extreme SGA, comorbid systemic
diseases, and high risk of mortality may feel fortunate for
the survival of their child and, comparatively, may not be-
lieve short stature is as important an outcome. In particu-
lar, among children born SGA with a poor cognitive
developmental prognosis, height may be considered un-
important. Parents may simply be pleased to have a rea-
sonably healthy child after a difficult beginning and they
may not seek treatment for short stature until the child isolder than the optimal referral age. Parents need to be
educated that most children born SGA will do well devel-
opmentally, that children without spontaneous catch-up
growth are highly likely to remain short as adults, and
that GH treatment, when initiated at an early age, will
improve childhood growth rate and AH.
Alternatively, delayed referral could be due to beliefs
of the treating pediatrician or primary care physician.
Children born SGA typically leave the care of neonatol-
ogists before they are 2 years old and receive care from
a pediatrician or primary care physician. Pediatricians
and primary care physicians may not consider height to
be a concern among patients who are short but healthy
until the optimal referral age has passed. It is important
to educate families and physicians about the significance
of the age of referral because studies show younger age at
GH treatment initiation is an important predictor of
response to GH therapy [15,18,19].
Younger age and growth response to GH treatment
Effectiveness of GH treatment in short-statured children
born SGA has been well demonstrated [12,13,42,43]. A
4-year study of GH treatment in SGA and GHD children
enrolled in the NordiNetW international outcome study
(IOS) demonstrated similar height improvement in
SGA and GHD children, supporting the idea that GH
treatment in non-GHD patients is as effective as it is in
GHD children [44]. The cumulative mean height stand-
ard deviation score (ΔHSDS) was 1.60 in SGA and 1.55
(P = 0.412) in GHD children, and height was within the
normal range after 4 years of GH treatment in 68% of
SGA children and 79% of GHD children.
A 2-year study of GH treatment in children enrolled
in the ANSWER Program registry found the largest
ΔHSDS at 1 and 2 years occurred in patients with
multiple pituitary hormone deficiency (MPHD) (0.85,
1.20; year 1, year 2) and SGA (0.80, 1.18), compared
with GHD (0.61, 1.06), idiopathic short stature (ISS)
(0.54, 0.90), and Turner Syndrome (TS) (0.50, 0.82)
patients [40]. After 2 years of GH treatment among
children enrolled in the IOS and ANSWER Program,
greater ΔHSDS was found for patients with SGA
compared with GHD (1.03 versus 0.97; P = 0.047).
However, therapeutic response is variable and age at
GH treatment initiation is a critical factor in predicting
growth outcome. Mathematical models developed to
predict optimal growth following GH therapy in children
born SGA show younger age at treatment initiation is a
key predictor of growth response [19,45]. The most
important determinants of greater first-year growth
during GH therapy in short children born SGA were
younger age and higher dose of GH [19,45]. The models
show growth velocity during the first year of treatment,
which is significantly influenced by age at treatment
Houk and Lee International Journal of Pediatric Endocrinology 2012, 2012:11 Page 4 of 8
http://www.ijpeonline.com/content/2012/1/11initiation, is the most important predictor of subsequent
growth, suggesting AH outcome is indicated by the initial
response to GH [19]. Greater long-term growth response
observed in AH SDs in children born SGA was shown to
depend on the duration of GH treatment, with younger
age at treatment initiation and longer phase of treatment
producing greater height increases [45].
Younger age at GH treatment initiation is asso-
ciated with greater short-term height response (see
Table 1 [15,16,19,46,47]). A comparison among chil-
dren born SGA and enrolled in NordiNet IOS from 5
European countries (N = 433) found the greatest
changes in height standard deviation score (ΔHSDS)
occurring during the first year of GH treatment in coun-
tries where children were younger (mean age 6.7) at treat-
ment initiation (P< 0.0001) [16]. Among males, the
change from baseline ΔHSDS in the first year of GH treat-
ment was significantly greater for patients who started
GH treatment at a younger age (ie, younger than age 11
[ΔHSDS = 0.82, N = 101], than it was for patients who
were older than age 11 [ΔHSDS = 0.27, N = 30], P<
0.0001) [15]. ΔHSDS in years 1–2 of GH treatment was
greater in SGA patients enrolled in the NordiNet IOS (N
= 423) who were younger at GH treatment initiation [18].Table 1 Age at treatment initiation and short-term GH treatm
Study N Design/Duration Agea/Model
Argente 2007 [46] 39b MC, C, R, O/2 years 2 to <4 year
4 to 5 years
Carvalho-Furtado
2009 [47]
39 Ob/1 year Prepubertal
Pubertal
Lee 2008 [16] 433 MC, NordiNet
IOS/≥1 year
Mean age 6.7














aAge at treatment initiation; bData are reported for study group 1 with 2 years GH t
start of treatment. ANSWER, American Norditropin Studies: Web-enabled Research;
velocity; IOS, international outcome study; KIGS, Pharmacia International Growth Da
standard deviation score.ΔHSDS following 1 year of GH treatment was significantly
greater in prepubertal (ΔHSDS = 0.75, N = 24) compared
with pubertal (ΔHSDS = 0.40, N = 15, P = 0.016) short-stat-
ured SGA children [47]. Among very young (ages 2–5)
SGA children, the greatest gain in growth velocity during
the first 2 years of GH treatment occurred in those
younger than age 4 (1.7 SDS, N = 16) compared with
children older than 4 (1.2 SDS, N = 23, P< 0.05) [46].
Younger age at initiation of GH treatment is also
associated with greater long-term height response (see
Table 2 [20,36-38,45,48]). In a long-term prediction
model of height SDS at the onset of puberty, younger
age at GH therapy initiation was associated with greater
height outcome at puberty in short-statured SGA children
(N = 150) [20]. Younger age at GH treatment initiation
was also associated with better AH following long-term
GH treatment in short SGA children (N = 38) [49].
Among 77 short-statured, prepubertal children born SGA,
better catch-up growth to AH in response to GH treatment
was noted in children who were younger at the start of GH
treatment (r = −0.56, P< 0.0001) [36]. Among children
treated for >2 years before puberty, the mean gain in
height was 1.7 SDS, compared with 0.9 SDS (P<0.001)
when treatment was initiated <2 years before the onset ofent outcomes in children born SGA
Outcome (ΔHSDS or statistical model) P Value
s 1.7 at 1 year; approximately 2.5 at 2 years <0.05
1.2 at 1 year; approximately 1.8 at 2 years
0.75 =0.016
0.40
to 9.3 6.7 years = 1.0 and 0.8;
7.6 years = 0.72;
8.3 years = 0.61;





Year 1: GH dose (35% of variability),
age at treatment start (11% of variability)
<0.0001
<0.0001
Year 2: HV in year 1 of treatment (29% of
variability), age at treatment start (3% of




Year 1 boys: <11 years = 0.82;
≥11 years = 0.27
Year 1 girls: <10 years = 0.58;
≥10 years = 0.41
Year 2 boys: <11 years = 1.23;
≥11 years = 0.59
Year 2 girls: <10 years = 1.00;





reatment; cMultivariate analysis showed ΔHSDS was dependent on age at the
C, controlled; GH, growth hormone; ΔHSDS, change in height SDS; HV, height
tabase; MC, multicenter; O, open trial; Ob, observational; R, randomized; SDS,
Table 2 Age at treatment initiation and long-term GH treatment outcomes in children born SGA
Study N Design/Duration Agea/Model Outcome (ΔHSDS or statistical model) P Value
Dahlgren 2005 [36] 77 Ob/prepubertal to FH Prepubertal during >2
years GH therapy vs
prepubertal during
<2 years GH therapy
Mean gain FH SDS prepubertal for
>2 years GH therapy = 1.7; prepubertal
for <2 years = 0.9
<0.001







Age at start (−0.27 estimated coefficient)
Other significant predictors: HSDS at start
(0.71 estimated coefficient), target height
SDS (0.13 estimated coefficient), GH dose X
IGF-I SDS at start (−0.29 estimated coefficient),




Ranke 2010 [45] 161 KIGS, clinical
trials/7.7 years
Median age 7.8 years/
Statistical models predicting
AH SDS and ΔHSDS
70% of variability in adult height SDS: HSDS
at GH start, ΔHSDS 1st year on GH, years on
treatment [younger start, longer phase],
maternal HSDS, length SDS at birth, SRS
diagnosis
NR
60% of variability in ΔHSDS: ΔHSDS 1st year
GH, H-MPH SDS at GH start, years of GH
treatment [younger start, longer phase]




ΔHSDS from start of GH treatment to AH
negatively correlated with age at treatment
start: r = −0.36
<0.01
aAge at treatment initiation. AH, adult height; C, controlled; DB, double-blind; FH, final height; GH, growth hormone; HSDS, height SDS; ΔHSDS, change in height SDS;
IGF-I, insulin-like growth factor; KIGS, Pharmacia International Growth Database; MC, multicenter; MPH, mid-parental height; NR, not reported; Ob, observational; R,
randomized; SDS, standard deviation score; SRS, Silver-Russell syndrome.
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duration, 7.8 years), in children born SGA (N= 54) resulted
in normalization of AH in most, with 98% reaching an AH
within their target height range; younger age at the start of
GH treatment was significantly associated with greater gain
in height SDS from the start of GH treatment until AH (r
= −0.36, P <0.01) [37]. Alternatively, GH treatment initi-
ation in short adolescents born SGA (mean age, 12.7 years)
has produced a more limited growth response with a mean
height gain of 1.1 SDS and 47% of treated patients reaching
AH in the normal range for the general population [50].
In addition to better growth outcomes, the greater
growth response to GH treatment among younger
patients born SGA may result in cost savings. A lower
GH dose of approximately 33 mcg/kg/day from treat-
ment initiation to AH is effective in children born SGA
not extremely short-statured (eg, height above −3 SD),
especially if treatment begins at ages 4–6 [51]. Children
beginning GH therapy in late prepuberty or extremely
short-statured at treatment initiation often receive a
higher dose (≥50 mcg/kg/day) for optimal short-term
catch-up growth, and then can be tapered back to 33
mcg/kg/day. Thus, a better cost of GH treatment-to-
height benefit outcome ratio may be achieved when GH
treatment begins at an early age because a greater
growth response occurs at a lower GH dose.
Safety of GH treatment in children born SGA
The long-term safety of GH treatment in childhood has
been under intense recent discussion due to the Safety
and Appropriateness of Growth hormone treatments inEurope (SAGhE) mortality data from France suggesting
increased all-cause, bone tumor-related, and circulatory
system disease-related mortality over the mean 17.3-year
follow-up period among adults who had received GH
treatment as children (N = 6928) for the diagnoses of
idiopathic isolated GHD, neurosecretory dysfunction,
idiopathic short stature or born SGA [52]. However, the
preliminary data from Belgium, The Netherlands, and
Sweden (N = 2543) contrasted with the report from
France in that the majority of the 21 deaths that oc-
curred over the follow-up period were due to accidents
or suicide and not a single case of death was related to
cancer or cardiovascular disease [53]. Questions have
been raised about the SAGhE data from France due to
methodological limitations of the study, including the
lack of an ideal control group of untreated patients, and
in August 2011, the FDA stated the evidence of
increased risk of death is inconclusive [54,55].
Additionally, multiple reports have demonstrated GH
is safe for use at currently recommended doses in short-
statured children born SGA [17,37]. GH treatment has
been shown safe across heterogeneous groups of chil-
dren born SGA, including very young (ages 2–5) chil-
dren born SGA, preterm (gestation ≤36 weeks) children
born SGA, and in children born SGA who were both
preterm and very young [46,56,57]. Continuous GH
treatment over 6 years was well tolerated in 54 children
with short stature born SGA [37]. Relative insulin resist-
ance occurred but there was no adverse effect on glucose
levels or development of diabetes and no GH related ad-
verse events were detected [37]. Similarly, among 84 SGA
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KIGS Database, a reduction in insulin sensitivity oc-
curred during GH treatment, but no patients devel-
oped impaired glucose tolerance or overt diabetes
mellitus [17].
The International SGA Advisory Board states that
because insulin resistance may increase during GH therapy,
reviewing for a family history of type 2 diabetes mellitus
(T2DM) is important [1]. Annual screening of carbohydrate
status, such as hemoglobin A1c, a fasting or postprandial
glucose, and insulin levels, is suitable in lean children
without a family history of diabetes. If pubertal children
are obese, have a family history of T2DM, or have
acanthosis nigricans, glucose homeostasis should be
monitored more frequently and intensely (using A1c in
addition to oral glucose tolerance test with insulin
measurements when indicated). Additionally, fasting
serum lipids and blood pressure should be periodically
monitored during long-term GH therapy.Conclusions
SGA diagnosis is challenging, and guidelines for the
selection of appropriate reference comparison data con-
tinue to evolve. Early diagnosis of SGA with failure to
show catch-up growth and early referral to GH therapy
are needed. In short-statured children born SGA without
catch-up growth, early referral for GH evaluation and
therapy is critical for optimal growth acceleration,
normalization of prepubertal height, and improvements
in AH. The average age of treatment referral varies, and
often exceeds the International Societies of Pediatric
Endocrinology and Growth Hormone Research Society
consensus guidelines (that recommend referral at ages
2–4) by many years. The reasons for this referral delay
are not known but likely involve parental and physician
attitudes about the importance of early growth in
children born SGA. Most children born SGA will do
well developmentally, and it is essential that parents
understand the benefits of GH treatment for short stature
that accrue at a younger age of treatment initiation. Opti-
mizing eventual height in short-statured patients born
SGA without catch-up growth is most efficiently done by
lowering the age of referral for GH evaluation and treat-
ment to a time in childhood where initiation of treatment
provides optimal benefit and aligns with consensus
recommendations for SGA management.Abbreviations
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